All participants were given sustained-release bupropion (but not nicotine replacement) for 7 weeks. Participants who reported complete avoidance of smoking during the 7th week and who showed no bodily evidence of nicotine were randomly assigned to one of two treatment groups: For the next 45 weeks, half of the participants continued to receive bupropion while the other half received an identical-appearing placebo pill. Neither the participants nor the evaluators were told which type of pill each participant was receiving. At monthly meetings, participants were questioned to see if they had remained free of cigarette smoking. To confirm reports of smoking abstinence, testing for evidence of nicotine in the body was done in participants who said that they had been free of cigarette smoking. After 1 year, treatment was stopped in both the bupropion and the placebo groups, but follow-up to detect smoking relapse continued for another year to evaluate the long-term effect of having received bupropion. Weight change over time was also recorded.